Repository logo
 
Publication

Enantiomeric fraction evaluation of pharmaceuticals in an aerobic granular sludge sequencing batch reactor

2015Conference object Open access
Simple item page
dc.contributor.authorAmorim, Catarina L.
dc.contributor.authorMoreira, Irina S.
dc.contributor.authorRibeiro, Ana R.
dc.contributor.authorSantos, Lúcia H. M. L. M.
dc.contributor.authorDelerue-Matos, Cristina
dc.contributor.authorTiritan, Maria E.
dc.contributor.authorCastro, Paula M. L.
dc.date.accessioned2015-09-11T09:32:55Z
dc.date.available2015-09-11T09:32:55Z
dc.date.issued2015
dc.description.abstractPharmaceutical compounds are emerging environmental contaminants that have received growing attention over the last two decades. Several of these pharmaceuticals currently in use are chiral. Therefore, the evaluation of the enantiomeric fraction (EF) of chiral pharmaceuticals (CPs), during the removal processes occurring in the environment, is crucial for assessing the fate of such micropollutants. Aerobic granular sludge (AGS) technology is one of the promising biotechnologies in wastewater treatment. However, due to its technological novelty, up to now there is a lack of information regarding the fate of pharmaceuticals on such technology. In this study, the enantioselective removal of a mixture of eight CPs was monitored in a laboratory-scale AGS bioreactor. A synthetic wastewater supplied with racemic mixture (1.3 µg/L of each enantiomer) of alprenolol, bisoprolol, metoprolol, propranolol, fluoxetine, its metabolite norfluoxetine, venlafaxine and salbutamol was used to continuously feed the bioreactor during 28 days. Quantification of the CPs in influent and effluent samples was carried after pre-concentration and cleanup by solid phase extraction and analysis by liquid chromatography tandem mass spectrometry using an Astec ChirobioticTMV, 5 um (150 × 2.1 mm i.d). Enantioselective monitoring of the fate of CPs during exposure revealed that the pharmaceutical norfluoxetine at effluent exhibited EF values ranging from 0.44 to 0.74, indicating stereoselective processes occurring during the treatment, with preferential removal of the (R)-enantiomer. On the other hand, non-enantioselective removal was observed for all other CPs. Furthermore, high removal efficiencies (>96%) for both (R)- and (S)-enantiomers were achieved for norfluoxetine. For fluoxetine, relatively minor removal efficiency was observed, with approximately 85% of each enantiomer being removed from the total influent load. Total concentrations of all other CPs were reduced by about 47–61%. This study suggests that EF evaluation of CPs could be an effective mean of gaining insights into the overall treatment performance.por
dc.identifier.citationAmorim, Catarina L. [et al.] - Enantiomeric fraction evaluation of pharmaceuticals in an aerobic granular sludge sequencing batch reactor. – In HPLC – 42nd International Symposium High Performance Liquid Phase Separations & Related Techniques, Geneva, Switzerland, 21-25 June, 2015por
dc.identifier.urihttp://hdl.handle.net/10400.14/18187
dc.language.isoengpor
dc.peerreviewednopor
dc.relationPEst-OE/EQB/LA0016/2014por
dc.relationFLUOROPHARMA - Biodegradation and removal of chiral and achiral fluorinated pharmaceuticals from wastewaters
dc.relationMETA-ANALYSIS IN AEROBIC GRANULAR SLUDGE BIOREACTORS FOR WASTEWATER TREATMENT
dc.relationMETAGENOMICS FOR BIODEGRADATION AND BIOCATALYTIC APPLICATIONS
dc.relationCHIRAL PHARMACEUTICALS IN THE ENVIRONMENT: ENANTIOMERIC RATIO AND BIODEGRADATION STUDIES
dc.relation.publisherversionhttp://www.hplc2015-geneva.org/wp-content/uploads/2015/05/150619_HPLC15_Poster-presentations.pdfpor
dc.subjectAerobic granular sludgepor
dc.subjectChiral pharmaceuticalspor
dc.subjectEnantiomeric fractionpor
dc.subjectStereoselectivitypor
dc.titleEnantiomeric fraction evaluation of pharmaceuticals in an aerobic granular sludge sequencing batch reactorpor
dc.typeconference object
dspace.entity.typePublication
oaire.awardTitleFLUOROPHARMA - Biodegradation and removal of chiral and achiral fluorinated pharmaceuticals from wastewaters
oaire.awardTitleMETA-ANALYSIS IN AEROBIC GRANULAR SLUDGE BIOREACTORS FOR WASTEWATER TREATMENT
oaire.awardTitleMETAGENOMICS FOR BIODEGRADATION AND BIOCATALYTIC APPLICATIONS
oaire.awardTitleCHIRAL PHARMACEUTICALS IN THE ENVIRONMENT: ENANTIOMERIC RATIO AND BIODEGRADATION STUDIES
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FEBB-EBI%2F111699%2F2009/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/FARH/SFRH%2FBPD%2F96481%2F2013/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/FARH/SFRH%2FBPD%2F87251%2F2012/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/FARH/SFRH%2FBD%2F64999%2F2009/PT
oaire.fundingStream3599-PPCDT
oaire.fundingStreamFARH
oaire.fundingStreamFARH
oaire.fundingStreamFARH
person.familyNameMoreira
person.familyNameTiritan
person.familyNameCastro
person.givenNameIrina Susana Sousa
person.givenNameMaria Elizabeth
person.givenNamePaula
person.identifierK-5841-2014
person.identifier1310409
person.identifier2013444
person.identifier.ciencia-id161E-A350-7FDE
person.identifier.ciencia-idD915-BFC0-FB3A
person.identifier.ciencia-id7C1F-6C72-354A
person.identifier.orcid0000-0001-6516-0994
person.identifier.orcid0000-0003-3320-730X
person.identifier.orcid0000-0001-8841-6606
person.identifier.ridK-5841-2014
person.identifier.ridK-9492-2014
person.identifier.ridM-8241-2013
person.identifier.scopus-author-id36798094100
person.identifier.scopus-author-id6602890981
person.identifier.scopus-author-id7102781782
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspor
rcaap.typeconferenceObjectpor
relation.isAuthorOfPublicationbb01f335-e184-4cb9-ae8a-70e62fdd5df3
relation.isAuthorOfPublication1ab8e8f5-cf82-4edd-89d8-46e5cca13e19
relation.isAuthorOfPublicationf2253992-dc8d-4042-9a0f-597ebcf0a1d6
relation.isAuthorOfPublication.latestForDiscoverybb01f335-e184-4cb9-ae8a-70e62fdd5df3
relation.isProjectOfPublicationcd03149f-4b91-4b1a-bca3-e6942eefd0db
relation.isProjectOfPublication35ef3d70-b0de-408a-b318-a2d6611ab273
relation.isProjectOfPublicationcb902d85-89e8-4694-8eb5-071f15153793
relation.isProjectOfPublicationf818ffd0-de77-40b2-9db1-cf359c3adc5d
relation.isProjectOfPublication.latestForDiscoverycd03149f-4b91-4b1a-bca3-e6942eefd0db

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
72697329.pdf
Size:
262.02 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.44 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

CBQF - Documentos de Conferências / Conference Objects